HAVANA, Cuba, Apr 17 (ACN) A clinical trial to test the safety and efficacy of a dose-ranging scale of non-alpha IL-2 Mutein, a product obtained at the Molecular Immunology Center, is being developed at the Hermanos Ameijeiras Clinical Surgical Hospital in Havana.
According to the oncologist Vilma Fleites, this drug is given to patients with advanced growing solid tumors who have been subjected to other treatments.
The study is now going through its second phase, with positive results revealing of the effectiveness of the anti-tumor therapy, she said.
“These trials are a major pillar for clinical oncologists, since they lead to the discovery and use of new care protocols with a view to the palliative care of patients with no other options in terms of oncological therapy”, the specialist remarked.
Cuban hospital develops clinical trial for patients with advanced tumors
Nos reservamos el derecho de no publicar los comentario que incumplan con las normas de este sitio